NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

Author's Avatar
Aug 13, 2020
Article's Main Image

-Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the treatment of cancer

-Combined company expected to trade on the NYSE American under a new ticker symbol

-Brooklyn already has $10 million of funding committed for post-merger activities

PR Newswire